{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:11:10Z","timestamp":1790075470631,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"URPP"},{"name":"BMS","award":["CA209-109 BMS018"],"award-info":[{"award-number":["CA209-109 BMS018"]}]},{"name":"BMS","award":["CA184-496"],"award-info":[{"award-number":["CA184-496"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.neo.2017.12.002","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:58:25Z","timestamp":1515718705000},"page":"218-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Lukas","family":"Kr\u00e4henb\u00fchl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Kerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Chevolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u00e8ve","family":"Brochez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil F","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2017.12.002_bb0005","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl. 5","key":"10.1016\/j.neo.2017.12.002_bb0010","doi-asserted-by":"crossref","first-page":"v194","DOI":"10.1093\/annonc\/mdq188","article-title":"Group EGW, Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Dummer","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2017.12.002_bb0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2017.12.002_bb0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs [mdash] from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neo.2017.12.002_bb0025","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2017.12.002_bb0030","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2017.12.002_bb0035","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2017.103","article-title":"PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma","volume":"31","author":"Atsaves","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2017.12.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T<sub>regs<\/sub> in the melanoma tumor microenvironment is driven by CD8<sup>+<\/sup> T Cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neo.2017.12.002_bb0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2017.01.011","article-title":"The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy","volume":"76","author":"Brochez","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.neo.2017.12.002_bb0050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.13100","article-title":"Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?","volume":"171","author":"Chevolet","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.neo.2017.12.002_bb0055","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ejca.2011.09.007","article-title":"Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients","volume":"48","author":"Speeckaert","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neo.2017.12.002_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096906","article-title":"Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients","volume":"214","author":"Weinlich","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.neo.2017.12.002_bb0065","series-title":"Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","author":"Gangadhar","year":"2017"},{"issue":"5","key":"10.1016\/j.neo.2017.12.002_bb0070","doi-asserted-by":"crossref","first-page":"v428","DOI":"10.1093\/annonc\/mdx377.001","article-title":"Epacadostat plus pemborlizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202\/KEYNOTE-037. ESMO. Madrid","volume":"28","author":"Hamid","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2017.12.002_bb0075","first-page":"w14183","article-title":"Data mining The Cancer Genome Atlas in the era of precision cancer medicine","volume":"145","author":"Cheng","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.neo.2017.12.002_bb0080","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neo.2017.12.002_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2017.12.002_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non\u2013small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.neo.2017.12.002_bb0095","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/jco.2014.32.15_suppl.3005","article-title":"Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475","volume":"32","author":"Richard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2017.12.002_bb0100","series-title":"Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma","author":"Ascierto","year":"2017"},{"key":"10.1016\/j.neo.2017.12.002_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1479-5876-11-54","article-title":"The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment","volume":"11","author":"Ascierto","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.neo.2017.12.002_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti\u2013PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.neo.2017.12.002_bb0115","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \u201ccancer immunogram\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558617304992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558617304992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T14:28:26Z","timestamp":1603636106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558617304992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1476558617304992"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2017.12.002","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}